Venture Life Group sells CDMO operations for €62 million

LONDON - Venture Life Group PLC (AIM:LON:VLG), a consumer healthcare company, has announced the sale of its contract development and manufacturing (CDMO) business and certain non-core products to BioDue S.p.A for €62 million (approximately £53 million). The transaction includes the entire share capital of Biokosmes SRL and Venture Life Manufacturing AB, which encompasses Kullgren Holdings AB and Rolf Kullgren AB.

The deal, which is expected to close in the third quarter of 2025, is subject to regulatory approvals under foreign direct investment regimes in Italy and Sweden. The cash proceeds from this sale will be utilized to pay down Venture Life’s existing debt and invest in the growth of its core brands and potential acquisitions in the UK, US, and Europe.

This strategic move allows Venture Life to streamline operations by divesting its lower-margin, capital-intensive manufacturing assets. The company will focus on expanding its "Power Brands," including Balance Activ, Health & Her/Him, Lift, Earol, Pomi T, and Gelclair, and further its franchise in women’s health.

Upon completion, the group will enter a decade-long development and manufacturing agreement with Biokosmes and Gnesta, ensuring continued production services for Venture Life’s products. This partnership is anticipated to bolster the company’s product innovation and development pipeline.

The divestiture is expected to result in a one-off profit of around £24.1 million for the financial year 2025. For the financial year ended December 31, 2024, the assets being sold had generated £20.5 million in revenue and £4.9 million in adjusted EBITDA.

As part of the transaction, Gianluca Braguti, a director at Venture Life since 2014, will step down from the company’s board but will continue with Biokosmes. The sale is seen as an opportunity for Venture Life to become a pure play consumer healthcare brand platform, focusing on proactive healthy longevity.

The company has confirmed that its audited results for the year ended December 31, 2024, will be released on June 19, 2025. Additionally, CEO Jerry Randall and CFO Daniel Wells are scheduled to present further details of the sale to investors via a webcast.

This news article is based on a press release statement from Venture Life Group PLC.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.